Nathalie Charland

Quebec, QC G1V3V9, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.

AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.

Journal: Science immunology
Published: April 05, 2024

A Hemagglutinin 1 Carrying Plant-Based Virus-like Particle Vaccine Generates an Efficacious Cellular Response by Exploiting IL-1 Signaling in Both Adult and Aged Mice.

A Hemagglutinin 1 Carrying Plant-Based Virus-like Particle Vaccine Generates an Efficacious Cellular Response by Exploiting IL-1 Signaling in Both Adult and Aged Mice.

Journal: ImmunoHorizons
Published: May 12, 2022

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.

Journal: The New England journal of medicine
Published: May 04, 2022

Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19.

Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19.

Journal: NPJ vaccines
Published: April 03, 2022

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Journal: NPJ vaccines
Published: November 14, 2021

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Journal: Nature communications
Published: October 28, 2021

Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.

Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.

Journal: Cellular & molecular immunology
Published: August 30, 2021

Projected impact of a plant-derived vaccine on the burden of seasonal influenza in Canada.

Projected impact of a plant-derived vaccine on the burden of seasonal influenza in Canada.

Journal: Human vaccines & immunotherapeutics
Published: July 02, 2021

Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.

Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.

Journal: NPJ vaccines
Published: July 20, 2018

Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin.

Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin.

Journal: Vaccine
Published: March 19, 2018

The adjuvant GLA-AF enhances human intradermal vaccine responses.

The adjuvant GLA-AF enhances human intradermal vaccine responses.

Journal: Science advances
Published: January 12, 2018

The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

Journal: Human vaccines & immunotherapeutics
Published: December 19, 2017
Showing 1-12 of 15

Last Updated: 09/26/2026